Elizabeth Timbrook Brown
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth Timbrook Brown has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Melissa R. Kaufman
Vanderbilt University Medical Center
5 shared publications - Roger R. Dmochowski
Department of Urology, Vanderbilt University Medical Center, Nashville, USA
5 shared publications - William Stuart Reynolds
Division of Reconstructive Urology and Pelvic Health, Department of Urology Vanderbilt University Medical Center Nashville Tennessee USA
5 shared publications - Joshua A. Cohn
Nashville, TN
3 shared publications Melissa R. Kaufman
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN
2 shared publicationsRoger R. Dmochowski
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN
2 shared publications
Latest Publications
- 10 October 2018
- Published by Springer Nature
- p. 243-262
Complications of Transobturator Synthetic Slings
- 10 October 2018
- Published by Springer Nature
- p. 243-262
Complications of Transobturator Synthetic Slings
- 26 July 2016
- Published by Wiley in Neurourology and Urodynamics
- Vol. 36 (4) , 1151-1154
Phenotyping women with detrusor underactivity by presumed etiology: Is it plausible?
Aims Underactive bladder (UAB) is a symptom complex with poorly characterized causation. The aim of this study was to determine if clinical and UDS parameters differed between categories of presumed detrusor underactivity (DU) etiologies. Methods A retrospective review was performed at a single institution from 2011 to 2015 to identify patients with symptoms of UAB. Patients were excluded if they were male, had anti‐incontinence, or pelvic organ prolapse (POP) surgery within 1 year, or the UDS did not demonstrate DU as defined within. Subjects were stratified by etiology into four cohorts: cardiovascular disease manifestations (CV), cardiac risk factors (CVR), neurologic (N), or idiopathic (I). Patient demographics, comorbidities, symptomatology, physical exam, and UDS parameters were compared. Results A total of 200 patients met inclusion criteria (CV: n = 53 [26.5%], CVR: n = 44 [22%] N: n = 81 [40.5%], I: n = 22 [11%]). Women in the CV cohort were significantly older and more likely to be post‐menopausal (P < 0.001). There were no differences between cohorts for BMI (P = 0.48), recurrent UTI (P = 0.63), history of urinary retention (AUR) (P = 0.65), POP (0.49), American Urological Association Symptom Score (AUA‐SS) (P = 0.06), presenting symptomatology [urgency, frequency, urgency urinary incontinence, AUR, incomplete emptying, hesitancy, UTI (P = 0.97)], or UDS parameters (first sensation [P = 0.25], normal desire [P = 0.80], strong desire [P = 0.58], capacity [P = 0.11], Qmax [P = 0.50], Pdet at Qmax [P = 0.22], post‐void residual [P = 0.82]). Conclusions Though differences were observed between cohorts for age and menopausal status, clinical or urodynamic parameters did not demonstrate distinct differences across presumed categories of etiology, suggesting that the etiology of DU may be multifactorial. Neurourol. Urodynam. 36:1151–1154, 2017.
- 26 July 2016
- Published by Wiley in Neurourology and Urodynamics
- Vol. 36 (4) , 1151-1154
Phenotyping women with detrusor underactivity by presumed etiology: Is it plausible?
Aims Underactive bladder (UAB) is a symptom complex with poorly characterized causation. The aim of this study was to determine if clinical and UDS parameters differed between categories of presumed detrusor underactivity (DU) etiologies. Methods A retrospective review was performed at a single institution from 2011 to 2015 to identify patients with symptoms of UAB. Patients were excluded if they were male, had anti‐incontinence, or pelvic organ prolapse (POP) surgery within 1 year, or the UDS did not demonstrate DU as defined within. Subjects were stratified by etiology into four cohorts: cardiovascular disease manifestations (CV), cardiac risk factors (CVR), neurologic (N), or idiopathic (I). Patient demographics, comorbidities, symptomatology, physical exam, and UDS parameters were compared. Results A total of 200 patients met inclusion criteria (CV: n = 53 [26.5%], CVR: n = 44 [22%] N: n = 81 [40.5%], I: n = 22 [11%]). Women in the CV cohort were significantly older and more likely to be post‐menopausal (P < 0.001). There were no differences between cohorts for BMI (P = 0.48), recurrent UTI (P = 0.63), history of urinary retention (AUR) (P = 0.65), POP (0.49), American Urological Association Symptom Score (AUA‐SS) (P = 0.06), presenting symptomatology [urgency, frequency, urgency urinary incontinence, AUR, incomplete emptying, hesitancy, UTI (P = 0.97)], or UDS parameters (first sensation [P = 0.25], normal desire [P = 0.80], strong desire [P = 0.58], capacity [P = 0.11], Qmax [P = 0.50], Pdet at Qmax [P = 0.22], post‐void residual [P = 0.82]). Conclusions Though differences were observed between cohorts for age and menopausal status, clinical or urodynamic parameters did not demonstrate distinct differences across presumed categories of etiology, suggesting that the etiology of DU may be multifactorial. Neurourol. Urodynam. 36:1151–1154, 2017.
- 2 July 2016
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 11 (3) , 234-241
Diagnosis and Management of Male Genital Lichen Sclerosus
- 2 July 2016
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 11 (3) , 234-241
Diagnosis and Management of Male Genital Lichen Sclerosus
- 18 April 2016
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 11 (2) , 160-168
Evaluation and Management of Mid-Urethral Sling Complications
- 18 April 2016
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 11 (2) , 160-168
Evaluation and Management of Mid-Urethral Sling Complications
- 30 January 2016
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 11 (1) , 73-78
Lessons Learned from Mesh Litigation for Prolapse and Incontinence
- 30 January 2016
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 11 (1) , 73-78
Lessons Learned from Mesh Litigation for Prolapse and Incontinence
- Open Access
- 1 January 2015
- Published by SAGE Publications in Clinical Medicine Insights: Urology
- Vol. 8 (8) , 1
Advances in the Treatment of Urinary Incontinence in Women
Urinary incontinence in women is quite prevalent today and management can be costly. Urinary incontinence can be minimal or quite bothersome, limiting activities of daily living. It is subdivided into urgency urinary incontinence, stress urinary incontinence, and mixed urinary incontinence. As such, treatment can vary immensely depending on the clinical presentations, ranging from behavioral modification to medicinal therapies to surgical procedures. First-line management for all urinary incontinence includes lifestyle and behavioral modifications. Historically, treatment options for urgency urinary incontinence were predominantly antimuscarinics, while more recent therapies include oral beta-3 agonist administration, sacral neuromodulation, onabotulinumtoxinA injection, and posterior tibial nerve stimulation. Stress urinary incontinence can be treated with a variety of urethral bulking agent injections or sling-based procedures using mesh, autologous fascia, or cadaveric fascia, as well as urethral intrasphincteric injections of autologous muscle-derived cells in new clinical trials. These recent advances that have been developed to help better curb urinary incontinence are discussed in this review.
- 1 January 2015
- Published by SAGE Publications in Clinical Medicine Insights: Urology
- Vol. 8 (8) , 1
Open AccessAdvances in the Treatment of Urinary Incontinence in Women
Urinary incontinence in women is quite prevalent today and management can be costly. Urinary incontinence can be minimal or quite bothersome, limiting activities of daily living. It is subdivided into urgency urinary incontinence, stress urinary incontinence, and mixed urinary incontinence. As such, treatment can vary immensely depending on the clinical presentations, ranging from behavioral modification to medicinal therapies to surgical procedures. First-line management for all urinary incontinence includes lifestyle and behavioral modifications. Historically, treatment options for urgency urinary incontinence were predominantly antimuscarinics, while more recent therapies include oral beta-3 agonist administration, sacral neuromodulation, onabotulinumtoxinA injection, and posterior tibial nerve stimulation. Stress urinary incontinence can be treated with a variety of urethral bulking agent injections or sling-based procedures using mesh, autologous fascia, or cadaveric fascia, as well as urethral intrasphincteric injections of autologous muscle-derived cells in new clinical trials. These recent advances that have been developed to help better curb urinary incontinence are discussed in this review.